QuidelOrtho Corporation (QDEL)
Automate Your Wheel Strategy on QDEL
With Tiblio's Option Bot, you can configure your own wheel strategy including QDEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QDEL
- Rev/Share 39.9353
- Book/Share 29.9471
- PB 0.8859
- Debt/Equity 0.1562
- CurrentRatio 1.7798
- ROIC -0.155
- MktCap 1802223756.0
- FreeCF/Share -0.0853
- PFCF -310.7282
- PE -1.5295
- Debt/Assets 0.056
- DivYield 0
- ROE -0.4364
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | QDEL | Citigroup | Buy | Neutral | -- | $33 | Oct. 7, 2025 |
| Upgrade | QDEL | Jefferies | Hold | Buy | -- | $44 | May 8, 2025 |
| Upgrade | QDEL | Citigroup | Neutral | Buy | $44 | $50 | Dec. 11, 2024 |
| Initiation | QDEL | Jefferies | -- | Hold | -- | $43 | Dec. 10, 2024 |
| Resumed | QDEL | UBS | -- | Neutral | $42 | $50 | Sept. 19, 2024 |
| Upgrade | QDEL | Craig Hallum | Hold | Buy | $40 | $57 | Sept. 5, 2024 |
News
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
QDEL continues to witness growth on the back of its strong product portfolio.
Read More
QuidelOrtho Unveils Results Manager System to Streamline Testing
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.
Read More
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.
Read More
QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant …
Read More
About QuidelOrtho Corporation (QDEL)
- IPO Date 1991-02-01
- Website https://www.quidelortho.com
- Industry Medical - Instruments & Supplies
- CEO Brian J. Blaser
- Employees 6600